Government of Colombia Declares Mandatory Insurance Coverage for Medical Cannabis Products
- last year
Khiron Life Sciences Corp announces that the new Colombian Government has included plant-based medical cannabis products in the list of mandatory insurance-covered medications as well as the signing of a first-of-its-kind medical cannabis contract with one of Colombia´s largest insurance companies based in the city of Bogota.
Resolution 2808 of 2022 was signed by the Ministry of Health. This revision was necessary to remove unintended ambiguities that had arisen whether plant-based magistral preparations from medical cannabis were also included in the insurance coverage. This is now once and for all clearly confirmed. The new government is fully committed with the use of medical cannabis as a covered treatment under the Colombian health system. The Government used this iteration to also validate medical conditions where they find moderate to strong evidence that cannabis is an effective treatment. These medical conditions evaluated by the IETS (Technical Institute of the health Sector) include chronic and neuropathic pain, oncology pain, sleep disorders, epilepsy, and fibromyalgia, which represent the primary conditions treated with Khiron products. Alvaro Torres, CEO of Khiron, comments: "Today is a great day for patients in Colombia and Khiron. We welcome the decision from the new Colombian government to categorically mandate insurance coverage for our medical cannabis products.
Resolution 2808 of 2022 was signed by the Ministry of Health. This revision was necessary to remove unintended ambiguities that had arisen whether plant-based magistral preparations from medical cannabis were also included in the insurance coverage. This is now once and for all clearly confirmed. The new government is fully committed with the use of medical cannabis as a covered treatment under the Colombian health system. The Government used this iteration to also validate medical conditions where they find moderate to strong evidence that cannabis is an effective treatment. These medical conditions evaluated by the IETS (Technical Institute of the health Sector) include chronic and neuropathic pain, oncology pain, sleep disorders, epilepsy, and fibromyalgia, which represent the primary conditions treated with Khiron products. Alvaro Torres, CEO of Khiron, comments: "Today is a great day for patients in Colombia and Khiron. We welcome the decision from the new Colombian government to categorically mandate insurance coverage for our medical cannabis products.